XML 38 R29.htm IDEA: XBRL DOCUMENT v3.19.1
The Company and its Significant Accounting Policies, Cash and Cash Equivalents through Future Accounting Pronouncements (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Earnings per share [Abstract]    
Common stock equivalents (in shares) 0 0
Potential dilution shares (in shares) 0 0
Advertising costs [Abstract]    
Advertising cost $ 0 $ 0
Future Accounting Pronouncements [Abstract]    
Total payments $ 200,000  
Gamma Knives [Member]    
Property, Plant and Equipment [Abstract]    
Estimated useful life 7 years  
Leasehold Improvements [Member]    
Property, Plant and Equipment [Abstract]    
Estimated useful life 7 years  
Office Furniture and Computers [Member] | Minimum [Member]    
Property, Plant and Equipment [Abstract]    
Estimated useful life 3 years  
Office Furniture and Computers [Member] | Maximum [Member]    
Property, Plant and Equipment [Abstract]    
Estimated useful life 7 years  
Corona Gamma Knife, LLC [Member]    
Investments in Unconsolidated Entities [Abstract]    
Investments in unconsolidated entities $ 0  
Neuro Partners, LLC [Member]    
Investments in Unconsolidated Entities [Abstract]    
Investments in unconsolidated entities 0  
Florida Oncology Partners, LLC [Member]    
Investments in Unconsolidated Entities [Abstract]    
Investments in unconsolidated entities 0  
Medical Oncology Partners LLC [Member]    
Investments in Unconsolidated Entities [Abstract]    
Investments in unconsolidated entities 0  
CB Oncology Partners LLC Member [Member]    
Investments in Unconsolidated Entities [Abstract]    
Investments in unconsolidated entities $ 0